The vesicular monoamine transporter is not regulated by dopaminergic drug treatments

Author： Borght T.V.   Kilbourn M.   Desmond T.   Kuhl D.   Frey K.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.294, Iss.2, 1995-12, pp. : 577-583

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of psychostimulants on vesicular monoamine transporter function

By Fleckenstein A.E.   Hanson G.R.  

European Journal of Pharmacology, Vol. 479, Iss. 1, 2003-10 ,pp. : 283-289

Elsevier

Access to resources Recommend Favorite

Binding of -dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific

By Kilbourn M.   Lee L.   Borght T.V.   Jewett D.   Frey K.  

European Journal of Pharmacology, Vol. 278, Iss. 3, 1995-05 ,pp. : 249-252

Elsevier

Access to resources Recommend Favorite

The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases

By  

Medicinal Chemistry, Vol. 11, Iss. 2, 2015-01 ,pp. : 104-108

Bentham Science Publishers

Access to resources Recommend Favorite

In vivo binding of (+)- -[ 3 H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies

By Kilbourn M.   Sherman P.  

European Journal of Pharmacology, Vol. 331, Iss. 2, 1997-07 ,pp. : 161-168

Elsevier

Access to resources Recommend Favorite

Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2

By Rehavi M.   Roz N.   Weizman A.  

European Neuropsychopharmacology, Vol. 12, Iss. 3, 2002-06 ,pp. : 261-268

Elsevier

Access to resources Recommend Favorite